BioSpace News Archive

Essilor commits to further expanding its unique inclusive business and philanthropic programmes to eradicate unprotected and uncorrected poor vision in the Kingdom of Bhutan, where 25% of the population suffer from uncorrected refractive errors and much of the population is at risk of exposure to UVA/UVB rays due to high altitude.

Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott released the following statement on new National Health Expenditure (NHE) data from the Centers for Medicare & Medicaid Services:

The global cardiovascular ultrasound imaging systems market 2019-2023 is expected to post a CAGR of more than 5% during the forecast period, according to the latest market research report by Technavio.

Today MEDISCA, the industry leader for providing high quality compounding solutions and services to pharmacists worldwide, announced that its Irving, Texas repackaging and distribution center received zero observations during its November 2018 current Good Manufacturing Practices (cGMP) inspection.

Aurora Cannabis Inc. (“Aurora” or the “Company”) (TSX: ACB) (NYSE: ACB) (Frankfurt: 21P; WKN: A1C4WM) announced today that the Company has established an exclusive partnership with Farmacias Magistrales S.A. (“Farmacias”), an established Mexican pharmaceutical manufacturer and distributer with a broad reach to approximately 80,000 retail points and 500 pharmacies and hospitals across Mexico

Data presented this week on wire-free radar breast localization demonstrated it may be a practical approach for positive axillary lymph node localization prior to neoadjuvant chemotherapy treatment (NAT) response.

Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced that new data on its EndoPredict® test will be presented by academic collaborators at the San Antonio Breast Cancer Symposium.

Orchard Therapeutics (NASDAQ: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies, today announced the appointment of Alicia Secor to its board of directors

Acacia Pharma Group plc (“Acacia Pharma” or “the Company”), a pharmaceutical company developing and commercialising hospital products for US and international markets, announces that the US Food and Drug Administration (FDA) has accepted its resubmission of the New Drug Application (NDA) for BARHEMSYS

Increasing aging population and rise in plastic surgery are the major factor which is fueling the growth of extremity tissue expanders market over the forecast period.